- Published on
Medicine – Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a malignant lymphoid neoplasm characterised by the presence of Reed–Sternberg cells in an appropriate inflammatory cellular background.
It is predominantly a B-cell-derived lymphoma and commonly presents with painless lymphadenopathy, particularly involving cervical, supraclavicular and mediastinal lymph nodes.
Unlike many non-Hodgkin lymphomas, Hodgkin lymphoma often spreads in a relatively predictable, contiguous pattern between adjacent lymph node groups.
Hodgkin lymphoma is a potentially curable lymphoid malignancy. Classical Hodgkin lymphoma is characterised by Hodgkin/Reed–Sternberg cells, usually expressing CD15 and CD30.
1. Classification
Hodgkin lymphoma has traditionally been divided into classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.
| Classification | Characteristics |
|---|---|
| Classical Hodgkin lymphoma (cHL) | Approximately 90–95% of cases; characteristic Reed–Sternberg cells, usually CD15+ and CD30+ |
| Nodular lymphocyte-predominant disease | LP or “popcorn” cells; typically CD20+ and CD45+, usually CD15− and CD30− |
Classical Hodgkin Lymphoma Subtypes
- Nodular sclerosis: Common subtype, often associated with mediastinal disease.
- Mixed cellularity: Reed–Sternberg cells in a mixed inflammatory background.
- Lymphocyte-rich: Numerous reactive lymphocytes with relatively few malignant cells.
- Lymphocyte-depleted: Rare subtype with relatively few background lymphocytes.
2. Pathophysiology
Classical Hodgkin lymphoma develops from abnormal germinal-centre B cells.
The malignant Hodgkin/Reed–Sternberg cells usually represent only a minority of cells within the tumour. They are surrounded by reactive lymphocytes, eosinophils, macrophages and other inflammatory cells.
Cytokines and chemokines released by the malignant cells recruit inflammatory cells and contribute to lymph node enlargement and systemic symptoms.
Pathophysiology Flowchart
3. Reed–Sternberg Cells
Reed–Sternberg cells are large abnormal cells that may contain two nuclei or a bilobed nucleus with prominent eosinophilic nucleoli.
The classical appearance is often described as an “owl's-eye” appearance.
Schematic of a Reed–Sternberg Cell
Simplified educational illustration; not a histological image.
Characteristic Features
- Large binucleated or multinucleated cells.
- Prominent eosinophilic nucleoli.
- Classical “owl's-eye” appearance.
- Usually positive for CD30 and CD15 in classical Hodgkin lymphoma.
- Usually negative or weakly positive for CD20, with weak PAX5 expression.
4. Clinical Features
A. Painless Lymphadenopathy
The most common presentation is painless lymph node enlargement.
Approximately 80% of patients have lymphadenopathy above the diaphragm at presentation.
Commonly affected sites include:
- Cervical lymph nodes.
- Supraclavicular lymph nodes.
- Mediastinal lymph nodes.
- Axillary lymph nodes.
B. B Symptoms
B symptoms may occur in approximately 30–40% of patients, although their frequency varies by stage and population.
| B Symptom | Definition |
|---|---|
| Fever | Unexplained temperature above 38°C |
| Night sweats | Drenching night sweats |
| Weight loss | Unintentional loss of more than 10% of body weight within six months |
C. Alcohol-Induced Lymph Node Pain
Pain at sites of involved lymph nodes following alcohol consumption is an unusual but classically associated feature of Hodgkin lymphoma.
It occurs in a small minority of patients, traditionally reported in fewer than 10%, and is not sufficiently sensitive or specific to establish the diagnosis.
D. Pel–Ebstein Fever
Pel–Ebstein fever is a historically described cyclical fever pattern consisting of:
- Febrile episodes lasting approximately 1–2 weeks.
- Alternating afebrile periods lasting approximately 1–2 weeks.
Its occurrence and diagnostic specificity are uncertain, and it has limited diagnostic value in modern clinical practice.
E. Hepatosplenomegaly
Hepatomegaly and splenomegaly may occur, particularly in advanced disease.
F. Other Manifestations
- Pruritus.
- Fatigue.
- Chest discomfort.
- Cough or dyspnoea due to mediastinal lymphadenopathy.
- Rarely, superior vena cava obstruction.
- Cytopenias in advanced disease or with bone marrow involvement.
5. Investigations
A. Lymph Node Biopsy
Excisional lymph node biopsy is preferred when feasible.
Histopathological examination identifies the characteristic malignant cells and inflammatory background, while immunohistochemistry establishes the lymphoma subtype.
B. Blood Investigations
| Investigation | Possible Finding |
|---|---|
| Full blood count | Anaemia, leukocytosis, lymphopenia or eosinophilia |
| ESR | May be elevated; useful in selected risk assessments |
| LDH | May be elevated but is nonspecific |
| Liver function | May be abnormal with hepatic involvement or other causes |
| Renal function | Baseline assessment before treatment |
| Infection screening | HIV and hepatitis testing as indicated before therapy |
C. Imaging
FDG-PET/CT is the preferred staging investigation for most patients with classical Hodgkin lymphoma.
It identifies nodal and extranodal involvement and is useful for assessing treatment response.
D. Bone Marrow Examination
Routine bone marrow biopsy is generally not required when adequate PET/CT staging is available for classical Hodgkin lymphoma.
It may be considered in selected circumstances where findings are uncertain or alternative diagnoses are suspected.
Diagnostic Flowchart
6. Ann Arbor / Lugano Staging
Hodgkin lymphoma is staged according to the anatomical distribution of disease, commonly using the Lugano classification based on the Ann Arbor system.
| Stage | Description |
|---|---|
| I | Single lymph node region or a single localized extranodal site |
| II | Two or more lymph node regions on the same side of the diaphragm |
| III | Lymph node regions on both sides of the diaphragm |
| IV | Diffuse or disseminated extranodal involvement, such as liver, bone marrow or lungs |
A and B Suffixes
- A: Absence of B symptoms.
- B: Presence of one or more B symptoms.
For example, stage IIB indicates involvement of two or more lymph node regions on the same side of the diaphragm, with B symptoms.
Bulky disease and other clinical risk factors are also important when selecting treatment.
Staging Diagram
Simplified conceptual diagram; not an anatomical staging image.
7. Management of Hodgkin Lymphoma
Hodgkin lymphoma is frequently curable, including in many patients with advanced disease.
Treatment depends on stage, disease bulk, risk factors, patient fitness and interim PET response.
A. Early-Stage Disease
Treatment options may include:
- Combination chemotherapy.
- Involved-site radiotherapy in selected patients.
- PET-adapted treatment strategies.
B. Advanced-Stage Disease
Systemic combination therapy is the mainstay of treatment.
Regimens may include:
- ABVD: Doxorubicin, bleomycin, vinblastine and dacarbazine.
- Nivolumab-AVD: A contemporary option for eligible patients with advanced classical Hodgkin lymphoma where approved and available.
- Brentuximab vedotin plus AVD: Another option in selected patients.
- Escalated BEACOPP or related intensive regimens: Used selectively in certain protocols.
The optimal regimen depends on patient characteristics, clinical guidelines and local availability.
C. Relapsed or Refractory Disease
Treatment options include:
- Salvage systemic therapy.
- Autologous stem cell transplantation in eligible patients.
- Brentuximab vedotin.
- PD-1 inhibitors, including nivolumab or pembrolizumab.
- Other specialised therapies.
D. Supportive Care and Follow-Up
- Management of treatment-related infections and cytopenias.
- Fertility preservation counselling when appropriate.
- Monitoring for cardiopulmonary toxicity.
- Assessment for late effects, including second malignancies and cardiovascular disease.
Treatment Flowchart
8. Hodgkin vs Non-Hodgkin Lymphoma
| Feature | Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
|---|---|---|
| Characteristic cells | Reed–Sternberg cells in classical HL | Variable malignant lymphoid cells |
| Cellular origin | Usually germinal-centre B cells | B, T or NK cells |
| Spread | Often contiguous | Often less predictable |
| Mediastinal involvement | Common in some subtypes | Variable |
| Extranodal involvement | Less common at presentation | More common in many subtypes |
| Treatment | Systemic therapy ± radiotherapy | Highly subtype-dependent |
| Prognosis | Frequently curable | Varies widely by subtype |
9. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Disease | B-cell-derived lymphoid malignancy |
| Characteristic cell | Reed–Sternberg cell |
| Classical immunophenotype | CD15+, CD30+, weak PAX5+ |
| Common presentation | Painless cervical or supraclavicular lymphadenopathy |
| Distribution | Frequently above the diaphragm |
| B symptoms | Fever, night sweats, weight loss |
| Classical associated feature | Alcohol-induced nodal pain |
| Historical fever pattern | Pel–Ebstein fever |
| Diagnosis | Excisional lymph node biopsy when feasible |
| Staging | FDG-PET/CT with Lugano classification |
| Treatment | Combination systemic therapy ± radiotherapy |
| Prognosis | Often curable |
10. Key Examination Pearls
- Reed–Sternberg cells are characteristic of classical Hodgkin lymphoma.
- Classical Hodgkin lymphoma is a B-cell-derived malignancy.
- Painless cervical or supraclavicular lymphadenopathy is a common presentation.
- Mediastinal lymphadenopathy is particularly associated with nodular sclerosis classical HL.
- B symptoms are unexplained fever, drenching night sweats and weight loss exceeding 10% over six months.
- Alcohol-induced nodal pain is uncommon but classically associated with Hodgkin lymphoma.
- Pel–Ebstein fever is a historical description and has limited diagnostic utility.
- Excisional lymph node biopsy is preferred for diagnosis.
- FDG-PET/CT is central to staging and response assessment.
- Bone marrow biopsy is usually unnecessary when adequate PET/CT staging is available.
- Hodgkin lymphoma is often curable with modern treatment.
A patient with persistent painless cervical lymphadenopathy, mediastinal lymph node enlargement and B symptoms should raise suspicion of Hodgkin lymphoma. Diagnosis requires tissue biopsy demonstrating the characteristic pathology and immunophenotype.
Rapidly progressive chest symptoms, airway compromise or suspected superior vena cava obstruction require urgent medical assessment. Treatment should be individualised by a specialist haematology team.
Kembara Xtra – Medicine Revision Notes